Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Adaptive, Adjunct, Albany, Alexandra, Amazon, Amgen, AON, Asia, asour, Bachelor, BBA, Beckman, Biomedicine, Boulder, cadet, Calgary, Cambridge, Cellastra, Centre, CMO, CMP, College, Columbia, convalescent, Couture, CSO, cultivation, dayof, deduction, Duarte, Elmcrest, eMTA, Fountain, graduate, Hancock, Hondo, Hosch, intitial, Keck, Larry, lecturer, licensure, Locomotion, Manitoba, Montebello, Museum, oTRANSITION, Pacific, Park, Pasadena, Philosophical, Physarum, Poetry, Quantason, regional, rehabilitation, resigned, retrospectively, Rio, round, Sixal, Snukal, Summit, Sussex, Sycamore, Talk, TfR, toblock, treatement, unbranched
Removed:
BEE, belief, BioEnergy, Cyber, exploring, HWO, lease, MSEE, partially, rent, Roex, sound, space, Store, Surpluzz, Web
Financial report summary
?Competition
Celldex Therapeutics • EOM Pharmaceutical • Geron • Northwest Biotherapeutics • Liquidia • Palisade BioManagement Discussion
- Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation
- This management’s discussion and analysis of financial condition and results of operations should be read in conjunction with the Company’s financial statements and the related notes, and the other financial information included in this Report.
- The Company was founded to commercialize new cancer treatment science and imaging targeting technology as well as a proprietary molecular delivery platform designed to interfere with those targets in order to inhibit and finally eradicate tumor progression. The Company is the exclusive licensee of certain intellectual property rights owned by Cedars Sinai Medical Center (“CSMC”) in Los Angeles, one of the nation’s premiere research institutions (the “License”). CSMC has developed a family of related nano-biopolymers conjugates (collectively referred to here as Polycefin™), believed capable of acting as a drug delivery and targeting platform for cancer therapy and imaging.